U.S. FDA Center for Devices and Radiological Health Update

Slides:



Advertisements
Similar presentations
Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Barbara Grenell, Preferred Health Strategies.
Advertisements

1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Regulatory Pathway for Platform Technologies
Overview of FDA Device Regulations
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
Medical Device User Fee Reauthorization & FDA Update Roadmap to a Successful 510(K) Submission For Your Medical Device August 22, 2012.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Work product for review and discussion by the FDASIA Regulation Subgroup; May not reflect the subgroup’s views REGULATORY WEAKNESSES A report of the typist.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
1 Medical Device User Fee and Modernization Act (MDUFMA II) Legislative Recommendations April 30, 2007.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.
FDA Regulatory and Compliance Symposium
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Investigational Devices and Humanitarian Use Devices June 2007.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
Fireside Chat Playing By The Rules: Navigating The Regulation Pathway Plamena Entcheva-Dimitrov, PhD, RAC, Founder and Principal Consultant – PREFERRED.
Medical Device Regulations in Canada; Key Challenges and International Initiatives.
ValGenesis Closed Loop Change Management ValGenesis, Inc Christy Street, Fremont, CA Ph:
1 Proposed Amendments to the Verification Procedure for In-Use Diesel Emission Control Strategies August 23, 2012 California Environmental Protection Agency.
Device Updates in FDASIA MDUFA III RA SAIC – 9 th April 2013 Karen Jaffe, MS, MBA, RAC or
November 6, 2013 Purchasing Controls & Supplier Quality Best Practices Beyond Compliance for the Medical Device Industry AdvaMed 2013 Bernie Liebler Technology.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
FDA's Two New Draft Guidance on Software and Device
Strengthening the Medical Device Clinical Trial Enterprise
Use of Postmarket Data to Support Premarket Approvals
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
What Are the FDA Requirements for Submitting an IDE?
Division of Cardiovascular Devices
Premarket Notification 510(k) process
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Director, Asia Pacific Japan and U.S. Clinical Operations
FDA Perspective on Cardiovascular Device Development
Balancing Pre and Postmarket Requirements Different Scenarios
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
The Current PMA Requirements
First-in-Man, First In The USA: What’s The Difference?
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
The NICE Citizens Council and the role of social value judgements
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
HSNO Reforms - Highlights Package
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
FDA-CDRH in the Next Decade A Vision for Change
HL7 International January Working Group Meeting Health Care Device WG
FDA 21 CFR Part 11 Overview June 10, 2006.
Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
IND Review Process Seoul National University
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Overview of the recommendations on software updates
Pharmaceuticals Industry
Regulatory Perspective of the Use of EHRs in RCTs
digital FDA Bakul Patel
Human Factors in Digital Health
Presentation transcript:

U.S. FDA Center for Devices and Radiological Health Update Jeff Shuren Director Center for Devices and Radiological Health  

Medical Device Accessories – Describing Accessories and Classification Pathway for New Accessory Types Guidance issued December 30, 2016. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidanced ocuments/ucm429672.pdf The guidance outlines an alternative approach for classifying a medical device accessory based on the risks it poses when used with the parent device rather than automatically classifying the accessory under the same class of the parent device. This guidance describes a medical device accessory as a device intended to support, supplement, and/or improve the performance of other medical devices when used together. The guidance describes the current processes the FDA uses to classify medical device accessories, and encourages manufacturers to use the process that applies when requesting a risk-based classification. Medical Device Accessories – Describing Accessories and Classification Pathway for New Accessory Types Final Guidance  

Postmarket Management of Cybersecurity in Medical Devices Guidance issued December 28, 2016. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance /guidancedocuments/ucm482022.pdf Cybersecurity is a shared responsibility. To better ensure the cybersecurity of medical devices once they’re on the market, the FDA has issued final guidance that outlines steps manufacturers should take to continually address cybersecurity risks with their devices through the use of a risk management approach. This final guidance is part of FDA’s ongoing efforts to ensure the safety and effectiveness of medical devices as they face potential cyber threats, at all stages in the device’s lifecycle. Postmarket Management of Cybersecurity in Medical Devices Final Guidance  

Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance and Enforcement Decisions Final Guidance Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance and Enforcement Decisions Guidance issued December 27, 2016. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm506679.pdf To help maximize patient safety and medical device quality this final guidance clarifies how the agency may assess the benefits and risks of medical devices when making product availability, compliance, and enforcement decisions. When determining whether or not to take compliance or enforcement action that could directly affect a medical device’s availability, the FDA may consider relevant, reliable information relating to patient perspective(s) and real-world data, in addition to traditional scientific and clinical data. The guidance may also help medical device companies in conducting their own benefit-risk assessments when evaluating the appropriate response to certain issues, such as determining whether or not to initiate a recall to correct a defective product or remove it from the market.

21st Century Cures Act: Making Progress on Shared Goals for Patients 21st Century Cures Act enacted December 2016 Device-related provisions: Combination Product Innovation Breakthrough Devices Humanitarian Device Exemptions Recognition of Standards Class I and Class II Exemptions Classification Panels Non-local Institutional Review Boards CLIA Waiver Guidance Update Least Burdensome Cleaning Instructions and Validation Data 510(k) Modifications Guidance Clarifying Medical Software Regulation

Medical Device User Fee Amendments of 2017 (MDUFA 4) MDUFA 4 agreement between FDA and Industry reached in August 2016 and recommendations submitted to Congress in January 2017 Commitment Letter provides for improvements in the following areas: PMA, 510(k), De Novo, and Pre-Submission Meeting performance Quality Management Information Technology Commitment Letter provides for further development of the following programs: Patient Input Real-World Evidence Digital Health, including: Aligning software review with software development lifecycles Continuing our work developing digital health convergence efforts through IMDRF

Thank You